Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 8/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14369905 | 0.91 | PTGS2 (0.36) | PTGS2TLR9TLR8TLR7BCHE | |
| SCHEMBL9963643 | 0.90 | PTGS2 (0.45) | PTGS2TBK1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9963639 | 0.89 | PTGS2 (0.44) | PTGS2KDM1ATLR9TLR8TLR7 | |
| SCHEMBL9963660 | 0.89 | ACHE (0.41) | PTGS2TLR9TLR8TLR7BCHE | |
| SCHEMBL9963654 | 0.87 | PTGS2 (0.39) | PTGS2TBK1TLR9TLR8TLR7 | |
| SCHEMBL9963672 | 0.85 | PTGS2 (0.38) | PTGS2TBK1TLR9TLR8TLR7 | |
| SCHEMBL9963607 | 0.83 | ACHE (0.38) | PTGS2TLR9TLR8TLR7BCHE | |
| SCHEMBL9966071 | 0.83 | PTGS2 (0.36) | PTGS2TLR9TLR8TLR7 | |
| SCHEMBL9963641 | 0.82 | CHRM4 (0.35) | PTGS2TBK1TLR9TLR8TLR7 | |
| SCHEMBL9963658 | 0.82 | TP53 (0.42) | PTGS2CYP2D6CYP2C19TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032583-B1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258857-A1 | CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | PTGS2 2872/4885TBK1 4268/4885CYP1A2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.